Navigation Links
Insmed to Request Hearing Before NASDAQ Panel to Review NASDAQ Staff Determination
Date:6/20/2008

RICHMOND, Va., June 20 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today announced that it intends to request a hearing before The NASDAQ Listing Qualifications Panel ('the Panel") to appeal an earlier Staff Determination to delist the Company's common stock from The NASDAQ Capital Market.

Insmed received a letter from The NASDAQ Stock Market ("NASDAQ") on June 17, 2008 indicating that the Company had not regained compliance with NASDAQ's minimum bid price requirement of $1.00 per share for continued listing of Insmed's common stock on The NASDAQ Capital Market as set forth in Marketplace Rule 4310(c)(4) (the "Staff Determination"). As a result, the Company's common stock would be subject to delisting unless Insmed requests a hearing before the Panel. Following procedures set forth in The NASDAQ Marketplace Rule 4800 series; the Company intends to request a hearing before the Panel to review the Staff Determination. The hearing request will stay the delisting of Insmed's common stock, pending the decision of the Panel following the hearing, allowing the Company's common stock to continue to trade on The NASDAQ Capital Market. There can be no assurance, however, that the Panel will grant Insmed's request for continued listing of its common stock on The NASDAQ Capital Market.

In the event that the Panel determines not to grant the Company's request for continued listing of its common stock on The NASDAQ Capital Market, Insmed's common stock may become eligible for quotation and trading on the OTC Bulletin Board.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow-on biologics market may be unsuccessful, our common stock could be delisted from The NASDAQ Capital Market and other risks and challenges detailed in the Company's filings with the U.S. Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Insmed Announces First Quarter 2008 Financial Results
2. Insmed to Present at CBI Follow-On Biologics Conference
3. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
4. Insmed Announces Additional Information in Compliance With NASDAQ Rules
5. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
6. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
7. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
8. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
9. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
10. Insmed to Appeal Delisting Notification From Nasdaq
11. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... ... announced a new agreement with Bankok,Thailand-based Global Stem Cells Network (GSCN) to distribute ... 15 Latin American countries, including Mexico, Costa Rica, Dominican Republic, Colombia, Argentina, Nicaragua, ...
(Date:2/10/2016)... , Feb. 10, 2016 NX Prenatal Inc., ... proprietary NeXosome® technology for early warning of adverse ... most recent study by Dr. Thomas McElrath ... Society for Maternal Fetal Medicine,s (SMFM) annual meeting held ... th , 2016.  The presentation reported initial positive ...
(Date:2/10/2016)... -- Matchbook, Inc., a company specializing in procurement and ... today the appointment of Jim Shuman ... 25 years of experience in supply chain, logistics ... decades in executive level roles as the SVP ... most recently headed global logistics and procurement at ...
(Date:2/10/2016)... ... February 10, 2016 , ... PatientCrossroads ... on the secure online PatientCrossroads platform, has exceeded both its one-year and overall ... the PROMPT study, which seeks to advance understanding of the hereditary risks for ...
Breaking Biology Technology:
(Date:1/28/2016)... 2016 Synaptics (NASDAQ: SYNA ), a leading developer ... quarter ended December 31, 2015. --> ... 2016 increased 2 percent compared to the comparable quarter last year ... 2016 was $35.0 million, or $0.93 per diluted share. ... the first quarter of fiscal 2016 grew 9 percent over the ...
(Date:1/25/2016)... , Jan. 25, 2016  Glencoe Software, the world-leading ... and publication industries, will provide the data management solution ... (NPSC). ... Phenotypic analysis measures the ... organisms, allowing comparisons between states such as health and ...
(Date:1/21/2016)... India , January 21, 2016 ... According to a new market research report "Emotion Detection ... and Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020", published by ... is expected to reach USD 22.65 Billion by ...
Breaking Biology News(10 mins):